Stock Analysis
REGENXBIO Inc. (RGNX) Stock Analysis
REGENXBIO Inc. (RGNX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
REGENXBIO Inc. (RGNX) currently has an AIQ Score of 44/100, indicating a neutral setup. Value is the strongest factor at 56/100. Momentum is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RGNX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $8.53 |
| AIQ Score | 44/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $481.82M |
| P/E Ratio | -2.46 |
| Forward P/E | — |
| EPS | $0.43 |
| Revenue TTM | $108.02M |
| Dividend Yield | 0.00% |
| Beta | 0.94 |
| Volume | 1.03M |
| 52-week range | $5.46-$16.19 |
| RSI 14 | 31.69 |
| 50-Day SMA | $10.70 |
| 200-Day SMA | $10.28 |
| Analyst Price Target | $21.67 |
| Next Earnings | Nov 5, 2026 |
RGNX
OverviewRGNX Stock Analysis Summary
REGENXBIO Inc. (RGNX) currently has an AIQ Score of 44/100, indicating a neutral setup. Value is the strongest factor at 56/100. Momentum is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, RGNX has AIQ Score of 44/100 with Value base of 56/100 and fading Momentum at 26/100. Wait for component alignment before adding exposure.
Value (56/100) leads while Momentum (26/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.35% stock move · RGNX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RGNX Bullish or Bearish Right Now?
RGNX currently has a neutral overall setup. Value is the strongest factor at 56/100, while Momentum is weakest at 26/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +154.04% upside from the latest quote.
- - Momentum is weak at 26/100.
- - Price is -16.99% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (36 vs 2).
Current Consensus
RGNX's Technical Analysis Consensus is currently Strong Sell, with 2 buy, 7 neutral, and 36 sell votes. RGNX's 14-day RSI is 31.69, which places the stock in a weaker momentum range. RGNX's beta is 0.94, indicating market sensitivity broadly in line with the market.
What Changed in RGNX?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the RGNX Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RGNX Decision Framework
Public evidence layers, setup checks, and risk context for REGENXBIO Inc..
REGENXBIO Inc. (RGNX) Stock Analysis
REGENXBIO Inc. has an AIQ Score of 44/100 in a Neutral regime. Value is strongest at 56/100. Beta is 0.94, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RGNX is in a Neutral AIQ regime with score 44/100. |
| Signal Conflict | The primary conflict is that value leads at 56/100 while momentum lags at 26/100. |
| Factor Evidence | Momentum 26/100 · Value 56/100 · Quality 40/100 · Risk 55/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 56/100.
Momentum is 26/100 and RSI (14) is 31.7.
RGNX is in a Neutral regime at 44/100.
Risk factor is 55/100 with beta 0.94 and annual volatility 93.31%.
Current conflict: value leads at 56/100 while momentum lags at 26/100.
RGNX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RGNX Fundamentals
RGNX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RGNX Technical Analysis
RGNX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RGNX Stock Catalysts
Track RGNX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RGNX Dividend Analysis
RGNX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RGNX Financial Data
RGNX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RGNX Risk Analysis
RGNX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RGNX Stock News
RGNX stock news, market tone, recent headlines, and catalyst context.
RGNX vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: RGNX · RIGL · ROIV · RXRX · SRPT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RGNX Current stock | 44/100 | 56/100 | 26/100 | 55/100 | 0.33 | 93.31% | Current |
| RIGL Rigel Pharmaceuticals | 74/100 | 63/100 | 67/100 | 59/100 | 0.65 | 64.58% | RGNX vs RIGL |
| ROIV Roivant Sciences | 57/100 | 34/100 | 78/100 | 61/100 | 2.48 | 46.57% | RGNX vs ROIV |
| RXRX Recursion Pharmaceuticals | 36/100 | 34/100 | 34/100 | 58/100 | -0.19 | 71.78% | RGNX vs RXRX |
| SRPT Sarepta Therapeutics | 55/100 | 64/100 | 67/100 | 38/100 | 0.58 | 81.30% | RGNX vs SRPT |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RGNX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RGNX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RGNX Stock FAQ
What is RGNX stock price today?
REGENXBIO Inc.'s current stock price is $8.53. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RGNX bullish or bearish right now?
RGNX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RGNX's market cap?
RGNX's market cap is $481.82M based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RGNX's current P/E ratio?
RGNX's current P/E ratio is -2.46 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RGNX's RSI?
RGNX's 14-day RSI is 31.69 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RGNX above its 50-day and 200-day moving averages?
RGNX is -20.25% from its 50-day SMA and -16.99% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RGNX's next earnings date?
RGNX's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RGNX pay a dividend?
RGNX's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.